Wire · opportunities
FDA Grants Accelerated Approval to Dostarlimab for MSI-H/dMMR Rectal Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 October 2026 · Fusion42 review
The FDA granted accelerated approval to dostarlimab for adults with untreated stage II/III locally advanced rectal cancer characterized by MSI-H or dMMR, based on clinical trials demonstrating significant complete response rates and disease control without surgery for many patients.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 19 Oct 2026 and 25 Oct 2026.
◆ ◆ The Wire takeaway
You can now offer a non-surgical immunotherapy option for MSI-H/dMMR rectal cancer in the US, opening a new treatment path that reduces reliance on chemoradiation and surgery. This shifts how you approach patient management and positions you early in a biomarker-driven cancer therapy market.
◆ Coverage
15 sources · first reported 19 Oct 2026 · latest 25 Oct 2026
◆ Related on Wire
◆ Topics